Long‐Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo‐Controlled Observation in the ODYSSEY OUTCOMES Trial

• Shaun G. Goodman,
• Philippe Gabriel Steg,
• Yann Poulouin,
• Deepak L. Bhatt,
• Vera A. Bittner,
• Rafael Diaz,
• Genevieve Garon,
• Robert A. Harrington,
• J. Wouter Jukema,
• Garen Manvelian,
• Wanda Stipek,
• Michael Szarek,
• Harvey D. White,
• Gregory G. Schwartz

Affiliations

Shaun G. Goodman

Canadian VIGOUR Centre University of Alberta Alberta Edmonton Canada

Philippe Gabriel Steg

Université Paris‐Cité, INSERM (Institut National de la Santé Et de la Recherche Médicale) U1148, and Assistance Publique–Hôpitaux de Paris, Hôpital Bichat Paris France

Yann Poulouin

IT&M Stats Neuilly‐sur‐Seine France

Deepak L. Bhatt

Mount Sinai Heart, Icahn School of Medicine at Mount Sinai NY New York USA

Vera A. Bittner

Division of Cardiovascular Disease University of Alabama at Birmingham AL Birmingham USA

Rafael Diaz

Estudios Cardiológicos Latinoamérica Instituto Cardiovascular de Rosario Rosario Argentina

Genevieve Garon

Sanofi Quebec Montreal Canada

Robert A. Harrington

Stanford Center for Clinical Research, Department of Medicine Stanford University CA Stanford USA

J. Wouter Jukema

Department of Cardiology Leiden University Medical Center Leiden the Netherlands

Garen Manvelian

Regeneron Pharmaceuticals NY Tarrytown USA

Wanda Stipek

Sanofi NJ Bridgewater USA

Michael Szarek

CPC (Colorado Prevention Center) Clinical Research and Division of Cardiology University of Colorado School of Medicine CO Aurora USA

Harvey D. White

Lane Cardiovascular Services Auckland City Hospital Auckland New Zealand

Gregory G. Schwartz

University of Colorado School of Medicine Colorado Aurora USA